Company Overview of Five Prime Therapeutics, Inc.
Five Prime Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of protein therapeutics that block cancer and inflammatory disease processes. The company’s product candidates include FP-1039/GSK3052230, a protein therapeutic, which is in Phase 1b clinical trials for trapping and neutralizing cancer-promoting fibroblast growth factors (FGFs) involved in cancer cell proliferation and new blood vessel formation; FPA008, a Phase 1 clinical trial stage antibody that inhibits colony stimulating factor-1 receptor; and FPA144 is an antibody for inhibiting FGF receptor 2b, as well as to treat patients with gastric cancer and potentially other solid tumo...
Two Corporate Drive
South San Francisco, CA 94080
Founded in 2001
Key Executives for Five Prime Therapeutics, Inc.
Total Annual Compensation: $525.0K
Chief Business Officer
Total Annual Compensation: $362.8K
Chief Medical Officer and Senior Vice President
Total Annual Compensation: $350.0K
Compensation as of Fiscal Year 2013.
Five Prime Therapeutics, Inc. Key Developments
Five Prime Therapeutics, Inc. Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-15-2015 09:30 AM
Jan 6 15
Five Prime Therapeutics, Inc. Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-15-2015 09:30 AM. Venue: Westin St. Francis Hotel, San Francisco, California, United States. Speakers: Lewis T. Williams, Founder, Chief Executive Officer, President and Director.
Five Prime Mulls Acquisitions
Jan 5 15
Five Prime Therapeutics, Inc. (NasdaqGS:FPRX) is looking for acquisitions. Five Prime Therapeutics, Inc. has filed a follow-on equity offering in the amount of $75 million and intend to use the net proceeds from the sale for the licensing or acquisition of, or the development of, additional product candidates, technologies, compounds, other assets or complementary businesses and to invest in interest-bearing, investment-grade securities.
Five Prime Therapeutics, Inc.(NasdaqGS:FPRX) added to NASDAQ Biotechnology Index
Dec 22 14
Five Prime Therapeutics, Inc. will be added to the NASDAQ Biotechnology Index.
Similar Private Companies By Industry
Recent Private Companies Transactions
March 19, 2014